John Gabrielson, senior vice president at JSR Life Sciences and head of Similis Bio, talked about the challenges associated with launching a business venture like Similis Bio and how Similis Bio's business model differs from other biosimilar developers and their spin-offs.
John Gabrielson, senior vice president at JSR Life Sciences and head of Similis Bio, talked about the challenges associated with launching a business venture like Similis Bio and how Similis Bio's business model differs from other biosimilar developers and their spin-offs.
Transcript
Similis Bio is a relatively new company in the biosimilars game, being a biopharmaceutical business division of JSR Life Sciences. However, they are not the only new players—Novartis has announced spinning off Sandoz into a separate company and Merck has done the same with Organon. How is Similis Bio different from other biopharmaceutical companies and what are some of the challenges associated with launching a new company in this space?
Gabrielson: Yeah, Similis Bio actually differs quite a bit from the spin-offs you mentioned. One thing, Similis is focused exclusively on preclinical CMC [chemistry, manufacturing, and control] development of biosimilars. So, this includes things like analytical development, cell line and process development, and formulation development. From there, we find partners to take the products forward through clinical development and commercialization.
The other thing I wanted to mention, we aim to introduce new efficiencies into the biosimilar development paradigm, like multi-use data and purpose-built information packages. So, I think that also distinguishes us.
You also asked about challenges. Launching a new venture in the biosimilar space does have unique challenges. It's a rapidly growing sector of the industry and it's a highly competitive one. The market's crowded and we believe it's also, at this time at least, a very inefficient marketplace. And that's an area where I think we can really help.
We're reimagining what biosimilar development can look like in a global marketplace where the winning products will be both cost competitive, and have top tier quality.
Similis Bio’s business model functions by helping biopharmaceutical companies navigate the drug development process, improve efficiency, and reduce cost. How does Similis Bio work with other companies to achieve those goals and what does Similis Bio look for in a company partnership?
Gabrielson: Yeah, I appreciate the question on the business model and the partnership. So, first of all, our business model really seeks to do 2 things. We want to make biosimilar development faster and make it more cost effective.
We accelerate development by creating made to order assets ready to license eliminating, in some cases, up to 2 years of preclinical development and allowing companies to start nonclinical and clinical development immediately. We make biosimilar development more cost effective by making noncompetitive reference product information available to companies on a nonexclusive basis.
As it relates to our business model, we develop biosimilar products that are highly similar to the reference products and ready to enter clinical trials. Compared to novel biologics, biosimilars achieve most of their value during preclinical development before even 1 human is dosed. So, in this way, we're positioning Similis as a value creation engine for biosimilars.
I think a good partnership leverages the strengths and resources of each party. So, we look for companies with a long-term mindset, who value quality and with the resources to take the preclinical clinical biosimilars that we develop through clinical development and, eventually, marketing authorization. We need to have aligned values with our partners, and notably, this would include a mission to make high-quality biologics globally accessible.
Partnering for Biosimilar Security: India's Role in US Health Care Savings, Supply Chain Stability
May 9th 2024As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.